Miravant Medical Technologies (OTCMKTS:MRVT) vs. Traws Pharma (NASDAQ:TRAW) Critical Analysis

Traws Pharma (NASDAQ:TRAW) and Miravant Medical Technologies (OTCMKTS:MRVT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Traws Pharma and Miravant Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Traws Pharma	3,028.25%	-2,883.04%	512.82%
Miravant Medical Technologies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings for Traws Pharma and Miravant Medical Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1	1	1	0	2.00
Miravant Medical Technologies	0	0	0	0	0.00

Traws Pharma currently has a consensus target price of $8.00, indicating a potential upside of 515.38%. Given Traws Pharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Traws Pharma is more favorable than Miravant Medical Technologies.

Insider and Institutional Ownership

8.0% of Traws Pharma shares are held by institutional investors. 14.0% of Traws Pharma shares are held by insiders. Comparatively, 17.1% of Miravant Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Traws Pharma and Miravant Medical Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$230,000.00	45.16	-$166.52 million	$97.30	0.01
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A

Miravant Medical Technologies has lower revenue, but higher earnings than Traws Pharma.

Summary

Traws Pharma beats Miravant Medical Technologies on 7 of the 9 factors compared between the two stocks.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.